Retrospective off-label clinical trials in OPA1-related DOA patients have suggested some potential benefit of idebenone, with treated patients demonstrating recovery of visual parameters compared to untreated patients;22 however, a placebo-controlled trial in an Opa1 mouse model showed only a transient benefit of idebenone treatment.23 The gene discussed is OPA1; the disease is autosomal dominant optic atrophy.